

PHARMANUTRA SIGNS NEW INTERNATIONAL AGREEMENTS FOR THE DISTRIBUTION OF CETILAR® AND ULTRAMAG®

The new agreements with the partners Renapharma and Fresenius Kabi Austria mark the start of an important internationalisation project regarding the products in the Cetilar® and Ultramag® lines.

Pisa, 18th March 2019 - The process of expansion on international markets continues for PharmaNutra S.p.A., a leading pharmaceutical company in the iron-based nutritional supplements sector, listed on the AIM Market Italy (**Aim Italia - Ticker PHN**), which last week informed shareholders of the financial statements figures for 2018, characterised by growth in double figures, with revenue of € 46.7 million (+23% compared to 2017).

The latest developments in the international sphere regard the products in the Cetilar® line, the rapidly absorbed cream ideal for the symptomatic treatment of joint and muscle pain caused by trauma, which in the coming months is set to make its debut on three important EU markets, and the new Ultramag®, the magnesium nutritional supplement created thanks to the exclusive proprietary Sucrosomial® Technology.

Thanks to the agreement signed with Renapharma, already an established partner of PharmaNutra since 2014 for the distribution of SiderAL® Forte in the Scandinavian peninsula, Cetilar® will soon also be available in Sweden and Norway. In addition, the company founded in 2003 by the Lacorte brothers has also signed a contract with Fresenius Kabi Austria for the launch of Oleovital Magnesium (Ultramag®) and Oleovital Cetilar® on the Austrian market. The two new products will join the line of SiderAL® iron-based nutritional supplements that Fresenius Kabi has been exclusive distributor for on the Austrian market for several years.

These two new agreements are an important step forward in the international growth of the innovative, patented Cetilar® line, well known above all in the world of sport, thanks to the numerous partnerships established in recent years. PharmaNutra S.p.A. is the main sponsor of Parma Calcio football team in Serie A, the Cetilar Racing team competing in the 24 Hours of Le Mans and in the World Endurance Championship, as well as the famous 151 Miglia-Trofeo Cetilar sailing regatta.

Roberto Lacorte, Vice President of PharmaNutra, declares: *“The new agreements with the partners Renapharma and Fresenius Kabi Austria, with whom we already have an important, well established business relationship, are both confirmation of the value and mutual success of the existing partnerships and an acknowledgement of the major potential of our Cetilar® product line, continually expanding on foreign markets. The Cetilar® brand now enjoys an established reputation also at international level, and these new results are merely the beginning of a long-term process of expansion, which in the months to come will be taking important new steps that we will be pleased to share with our shareholders”.*

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 91 studies published involving more than 6000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com